Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • FE 203799Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Active Trials
0(0%)

Phase Distribution

Phase 1/2
1
100%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 1/2Combined phases
1(100.0%)

Highest Phase Reached

Phase 1/2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

1

all time

Status Distribution
Terminated(1)

Detailed Status

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
1
Active
0
Success Rate
N/A
Most Advanced
Phase 1/2

Trials by Phase

Phase 1/21 (100.0%)

Trials by Status

withdrawn1100%

Recent Activity

0 active trials
Showing 1 of 1
withdrawnphase_1_2

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

NCT03417765

Clinical Trials (1)

Showing 1 of 1 trials
NCT03417765Phase 1/2

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

Withdrawn

All 1 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
1